Diffuse Large B-Cell Lymphoma with High Risk of Central Nervous System Damage: A Literature Review, Prevention, Treatment, and Prognosis

Selmi Faikovna Ramazanova, A.V. Arakelyan, A.A. Semenova, O.Yu. Baranova, D.N. Tupitsyna, M.Yu. Kichigina, I.Z. Zavodnova, E.V. Paramonova, A.S. Antipova, V.O. Shpirko, Yu.I. Klyuchagina, U.G. Koshkina, G.S. Tumyan,

DOI:

https://doi.org/10.21320/2500-2139-2025-18-1-51-64

AIM. To assess the feasibility of preventing the CNS damage in intermediate/high risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in accordance with CNS-IPI criteria.

MATERIALS & METHODS. The trial was based on the clinical data from 60 patients with newly diagnosed DLBCL treated at the NN Blokhin National Medical Cancer Research Center from 2018 to 2024. The patients were 29–80 years of age (median 59 years); there were 34 women and 26 men. In accordance with the immunohistochemical algorithm of C.P. Hans, GCB subtype of DLBCL was identified in 18 (30 %) patients, non-GCB subtype was detected in 35 (58 %), and in 7 (12 %) patients subtype was not specified. By the time of primary DLBCL diagnosis, in 58 out of 60 patients tumor stage 4 was found, in 56 patients LDH increase was reported, and 22 patients showed ECOG ≥ 2. Extranodal lesions (> 1 zone) were identified in 53/60 patients. In accordance with the CNS-IPI score, with respect to CNS damage there were 22 (37 %) intermediate and 36 (60 %) high risk patients. In first-line therapy, R-CHOP (n = 40; 67 %) was most commonly used, R-DA-EPOCH (n = 10; 17 %) and Pola-R-CHP (n = 7; 11 %) were administered less often; 3 patients (5 %) received R-B. In 18 (30 %) patients, the initial lesions were treated with radiotherapy after completing drug chemotherapy. Different variants of CNS damage prevention in DLBCL included intrathecal (IT) administration of 3 drugs (methotrexate, cytarabine, and dexamethasone) and/or 2 methotrexate (МТХ) 3–3,5 g/m2 infusions. The trial identified two clinically comparable groups of DLBCL patients with CNS-IPI intermediate/high risk of CNS damage, who received chemotherapy throughout different periods of time (2018–2021 and 2022–2024). During the first period (n = 30), to prevent possible CNS damage, both methods were used as monotherapy or combined regimens consecutively. МТХ IT + МТХ HD (high dose) as prevention was administered to 20 (67 %) patients, 2 (7 %) patients received only МТХ HD, and 8 (26 %) patients received only МТХ IT. In the second group, CNS damage prevention was not provided for this category of DLBCL patients.

RESULTS. In the total group (n = 60), with the follow-up median of 24 months, the 2-year progression-free survival (PFS) was 76 % (median 44 months), whereas the 2-year overall survival (OS) was 87 % (median 49 months). Age > 60 years was associated with the worst rate of the 2-year PFS (72 %) compared with patients ≤ 60 years (90 %) (p = 0.04). Besides, the 2-year OS in women was 77 % and 100 % in men, whereas in the groups of patients with ECOG ≥ 2 vs. < 2 it was 63 % and 95 %, respectively (p = 0.04). In patients with prevention of CNS damage, the 2-year PFS was 95 % vs. 64 % in patients without it (p = 0.001), and the 2-year OS in them was 95 % and 77 %, respectively (p = 0.05). In the course of this trial, the rate of DLBCL relapses with CNS involvement was 5 % (n = 3). Relapses were detected in 6, 18, and 46 months from the beginning of chemotherapy. CNS damage prevention was not performed in 3 patients with relapses.

CONCLUSION. The data obtained in this ambispective trial support systemic and intrathecal use of methotrexate to increase the overall PFS rate and to reduce the relapse rate, also in CNS. The methods of CNS damage prevention are not associated with additional toxicity in DLBCL patients with intermediate/high CNS-IPI risk score.

  • Selmi Faikovna Ramazanova NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522 https://orcid.org/0009-0008-7084-0060 (unauthenticated)
  • A.V. Arakelyan NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522; ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет) Минздрава России, ул. Большая Пироговская, д. 2, стр. 4, Москва, Российская Федерация, 119435 https://orcid.org/0000-0003-4911-0959 (unauthenticated)
  • A.A. Semenova NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522 https://orcid.org/0000-0003-4951-3053 (unauthenticated)
  • O.Yu. Baranova NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522 https://orcid.org/0000-0002-0202-8176 (unauthenticated)
  • D.N. Tupitsyna NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522 https://orcid.org/0009-0003-4830-1160 (unauthenticated)
  • M.Yu. Kichigina NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522 https://orcid.org/0000-0002-2715-2528 (unauthenticated)
  • I.Z. Zavodnova NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522 https://orcid.org/0000-0001-6674-8634 (unauthenticated)
  • E.V. Paramonova NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522 https://orcid.org/0009-0008-7886-7671 (unauthenticated)
  • A.S. Antipova NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522 https://orcid.org/0000-0002-1731-8336 (unauthenticated)
  • V.O. Shpirko NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522 https://orcid.org/0000-0002-2300-0332 (unauthenticated)
  • Yu.I. Klyuchagina NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522; ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет) Минздрава России, ул. Большая Пироговская, д. 2, стр. 4, Москва, Российская Федерация, 119435 https://orcid.org/0000-0003-2748-9208 (unauthenticated)
  • U.G. Koshkina NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522 https://orcid.org/0009-0000-1023-5426 (unauthenticated)
  • G.S. Tumyan NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522; Russian Medical Academy of Postgraduate Education, 2/1 Barrikadnaya ul., Moscow, Russian Federation, 125993 ; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 23, Москва, Российская Федерация, 115522; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, ул. Баррикадная, д. 2/1, Москва, Российская Федерация, 125993 https://orcid.org/0000-0002-5771-4413 (unauthenticated)
  1. Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842–58. doi: 10.1056/NEJMra2027612. DOI: https://doi.org/10.1056/NEJMra2027612
  2. Gleeson M, Counsell N, Cunningham D, et al. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol. 2017;28(10):2511–6. doi: 10.1093/annonc/mdx353. DOI: https://doi.org/10.1093/annonc/mdx353
  3. Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol. 2002;13(7):1099–107. doi: 10.1093/annonc/mdf175. DOI: https://doi.org/10.1093/annonc/mdf175
  4. Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol. 2016;34(26):3150–6. doi: 10.1200/JCO.2015.65.6520. DOI: https://doi.org/10.1200/JCO.2015.65.6520
  5. El-Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer. 2017;75:195–203. doi: 10.1016/j.ejca.2016.12.029. DOI: https://doi.org/10.1016/j.ejca.2016.12.029
  6. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. doi: 10.1038/35000501. DOI: https://doi.org/10.1038/35000501
  7. Sehn LH, Martelli M, Trneny M, et al. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13(1):71. doi: 10.1186/s13045-020-00900-7. DOI: https://doi.org/10.1186/s13045-020-00900-7
  8. Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396–407. doi: 10.1056/NEJMoa1801445. DOI: https://doi.org/10.1056/NEJMoa1801445
  9. Ollila TA, Kurt H, Waroich J, et al. Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma. Blood. 2021;137(8):1120–4. doi: 10.1182/blood.2020007236. DOI: https://doi.org/10.1182/blood.2020007236
  10. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720–48. doi: 10.1038/s41375-022-01620-2. DOI: https://doi.org/10.1038/s41375-022-01620-2
  11. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891–901. doi: 10.1111/bjh.12982. DOI: https://doi.org/10.1111/bjh.12982
  12. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–61. doi: 10.1182/blood-2014-05-578963. DOI: https://doi.org/10.1182/blood-2014-05-578963
  13. Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127(18):2182–8. doi: 10.1182/blood-2015-10-676700. DOI: https://doi.org/10.1182/blood-2015-10-676700
  14. Wang X, Gao Y, Shan C, et al. Association of circulating tumor DNA from the cerebrospinal fluid with high-risk CNS involvement in patients with diffuse large B-cell lymphoma. Clin Transl Med. 2021;11(1):e236. doi: 10.1002/ctm2.236. DOI: https://doi.org/10.1002/ctm2.236
  15. Bobillo S, Crespo M, Escudero L, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2021;106(2):513–21. doi: 10.3324/haematol.2019.241208. DOI: https://doi.org/10.3324/haematol.2019.241208
  16. Tomita N, Yokoyama M, Yamamoto W, et al. The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis. Leuk Lymphoma. 2018;59(1):97–104. doi: 10.1080/10428194.2017.1330541. DOI: https://doi.org/10.1080/10428194.2017.1330541
  17. Eyre TA, Djebbari F, Kirkwood AA, Collins GP. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica. 2020;105(7):1914–24. doi: 10.3324/haematol.2019.229948. DOI: https://doi.org/10.3324/haematol.2019.229948
  18. Eyre TA, Kirkwood AA, Wolf J, et al. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. Br J Haematol. 2019;187(2):185–94. doi: 10.1111/bjh.16070. DOI: https://doi.org/10.1111/bjh.16070
  19. Ferreri AJ, Bruno-Ventre M, Donadoni G, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2015;168(5):654–62. doi: 10.1111/bjh.13194. DOI: https://doi.org/10.1111/bjh.13194
  20. Ong SY, de Mel S, Grigoropoulos NF, et al. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J. 2021;11(8):143. doi: 10.1038/s41408-021-00535-y. DOI: https://doi.org/10.1038/s41408-021-00535-y
  21. Puckrin R, El Darsa H, Ghosh S, et al. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma. Am J Hematol. 2021;96(7):764–71. doi: 10.1002/ajh.26181. DOI: https://doi.org/10.1002/ajh.26181
  22. Lewis KL, Jakobsen LH, Villa D, et al. High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. J Clin Oncol. 2023;41(35):5376–87. doi: 10.1200/JCO.23.00365. DOI: https://doi.org/10.1200/JCO.23.00365
  23. Chua BJG, Low CE, Yau CE, et al. Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma. Exp Hematol Oncol. 2024;13(1):1. doi: 10.1186/s40164-023-00467-2. DOI: https://doi.org/10.1186/s40164-023-00467-2
  24. Wilson MR, Eyre TA, Kirkwood AA, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood. 2022;139(16):2499–511. doi: 10.1182/blood.2021014506. DOI: https://doi.org/10.1182/blood.2022015432
  25. Lewis KL, Jakobsen LH, Villa D, et al. High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-cell lymphoma: an international retrospective study of 2300 high-risk patients. Blood. 2021;138(Suppl 1):181. doi: 10.1182/blood-2021-146737. DOI: https://doi.org/10.1182/blood-2021-146737
  26. Orellana-Noia VM, Reed DR, McCook AA, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139(3):413–23. doi: 10.1182/blood.2021012888. DOI: https://doi.org/10.1182/blood.2021012888
  27. Bobillo S, Joffe E, Sermer D, et al. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. Blood Cancer J. 2021;11(6):113. doi: 10.1038/s41408-021-00506-3. DOI: https://doi.org/10.1038/s41408-021-00506-3
  28. Wilson MR, Eyre TA, Martinez-Calle N, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. Blood Adv. 2020;4(15):3586–93. doi: 10.1182/bloodadvances.2020002421. DOI: https://doi.org/10.1182/bloodadvances.2020002421
  29. Lee K, Yoon DH, Hong JY, et al. Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis. Int J Hematol. 2019;110(1):86–94. doi: 10.1007/s12185-019-02653-7. DOI: https://doi.org/10.1007/s12185-019-02653-7
  30. Goldschmidt N, Horowitz NA, Heffes V, et al. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse. Leuk Lymphoma. 2019;60(8):1890–8. doi: 10.1080/10428194.2018.1564823. DOI: https://doi.org/10.1080/10428194.2018.1564823
  31. McKay P, Wilson MR, Chaganti S, et al. The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper. Br J Haematol. 2020;190(5):708–14. doi: 10.1111/bjh.16866. DOI: https://doi.org/10.1111/bjh.16866
  32. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: B-cell lymphomas. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (accessed 11.11.2024).
  33. Hutchings M, Ladetto M, Buske C, et al. ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients. Ann Oncol. 2018;29(8):1687–700. doi: 10.1093/annonc/mdy167. DOI: https://doi.org/10.1093/annonc/mdy167
  34. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82. doi: 10.1182/blood-2003-05-1545. DOI: https://doi.org/10.1182/blood-2003-05-1545
  35. Wilson MR, Bobillo S, Cwynarski K. CNS prophylaxis in aggressive B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2022;2022(1):138–45. doi: 10.1182/hematology.2022000331. DOI: https://doi.org/10.1182/hematology.2022000331

Keywords:

diffuse large B-cell lymphoma, CNS-IPI, intermediate risk, high risk, prevention of central nervous system damage

License

Copyright (c) 2025 Clinical Oncohematology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.
2025-1

Downloads

Published

01.01.2025

Issue

Vol. 18 No. 1 (2025)
LYMPHOID TUMORS

How to Cite

Ramazanova S.F., Arakelyan A.V., Semenova A.A., et al. Diffuse Large B-Cell Lymphoma with High Risk of Central Nervous System Damage: A Literature Review, Prevention, Treatment, and Prognosis. Clinical Oncohematology. Basic Research and Clinical Practice. 2025;18(1):51–64. doi:10.21320/2500-2139-2025-18-1-51-64.

Most read articles by the same author(s)

1 2 3 4 > >>